Transitional cell carcinoma

20,432views

Transitional cell carcinoma

Watch later

Watch later

Myocardial infarction
Angina pectoris
Aortic dissection
Aneurysms
Shock
Cor pulmonale
Tricuspid valve disease
Pulmonary valve disease
Mitral valve disease
Aortic valve disease
Hypertrophic cardiomyopathy
Dilated cardiomyopathy
Restrictive cardiomyopathy
Pericarditis and pericardial effusion
Cardiac tamponade
Rheumatic heart disease
Endocarditis
Myocarditis
Premature ventricular contraction
Premature atrial contraction
Atrial fibrillation
Atrial flutter
Atrioventricular nodal reentrant tachycardia (AVNRT)
Wolff-Parkinson-White syndrome
Atrioventricular block
Bundle branch block
Long QT syndrome and Torsade de pointes
Ventricular tachycardia
Brugada syndrome
Ventricular fibrillation
Hypertension
Arterial disease
Vasculitis
Kawasaki disease
Behcet's disease
Deep vein thrombosis
Chronic venous insufficiency
Thrombophlebitis
Nutcracker syndrome
Superior mesenteric artery syndrome
Coronary steal syndrome
Lymphedema
Patent ductus arteriosus
Ventricular septal defect
Atrial septal defect
Coarctation of the aorta
Tetralogy of Fallot
Transposition of the great vessels
Persistent truncus arteriosus
Hypoplastic left heart syndrome
Vascular tumors
Arteriovenous malformation
Cardiac tumors
Angiosarcomas
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
ACE inhibitors, ARBs and direct renin inhibitors
Miscellaneous lipid-lowering medications
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
Positive inotropic medications
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
Adrenergic antagonists: Presynaptic
cGMP mediated smooth muscle vasodilators
Calcium channel blockers
IgA nephropathy (NORD)
Rapidly progressive glomerulonephritis
Goodpasture syndrome
Poststreptococcal glomerulonephritis
Lupus nephritis
Minimal change disease
Diabetic nephropathy
Membranoproliferative glomerulonephritis
Membranous nephropathy
Lower urinary tract infection
Acute pyelonephritis
Chronic pyelonephritis
Kidney stones
Renal tubular acidosis
Renal artery stenosis
Renal cortical necrosis
Renal azotemia
Postrenal azotemia
Chronic kidney disease
Hyponatremia
Hypernatremia
Hyperkalemia
Hypokalemia
Hypercalcemia
Hypocalcemia
Hypermagnesemia
Hypomagnesemia
Hyperphosphatemia
Hypophosphatemia
Neurogenic bladder
Urinary incontinence
Renal cell carcinoma
Angiomyolipoma
Nephroblastoma (Wilms tumor)
WAGR syndrome
Non-urothelial bladder cancers
Transitional cell carcinoma
Hydronephrosis
Vesicoureteral reflux
Posterior urethral valves
Bladder exstrophy
Polycystic kidney disease
Horseshoe kidney
Renal agenesis
Medullary sponge kidney
Multicystic dysplastic kidney
Medullary cystic kidney disease
Potter sequence
Parasympathetic nervous system
Central nervous system histology
Somatosensory pathways
Peripheral nervous system histology
Rheumatoid arthritis
Reactive arthritis
Psoriatic arthritis
Gout
Ankylosing spondylitis
Systemic lupus erythematosus
Scleroderma
Raynaud phenomenon
Limited systemic sclerosis (CREST syndrome)
Sjogren syndrome
Fibromyalgia
Polymyalgia rheumatica
Amyloidosis
Dermatomyositis
Polymyositis
Inclusion body myopathy
Osteoarthritis
Slipped capital femoral epiphysis
Paget disease of bone
Osteomalacia and rickets
Osteoporosis
Osgood-Schlatter disease (traction apophysitis)
Legg-Calve-Perthes disease
Septic arthritis
Osteomyelitis
Lordosis, kyphosis, and scoliosis
Rotator cuff tear
Meniscus tear
Compartment syndrome
Bone tumors
Developmental dysplasia of the hip
Cleidocranial dysplasia
Achondroplasia

Transcript

Watch video only

The most common form of cancer in the lower urinary tract—or the bladder and the urethra— is transitional cell carcinoma (or TCC), and to be more specific, urothelial cell carcinoma (or UCC).

While this cancer can affect tissues in the upper urinary tract, such as the renal pelvis and the ureter, it most commonly arises in the urothelium of the bladder.

The urothelium (or uroepithelium) is a specific type of transitional cell epithelium that lines the inner surface of much of the urinary tract. This tissue is composed of 3–7 cell layers, and it forms a tight barrier which holds urine without allowing toxins to move across the epithelium and back into the body.

That barrier function is largely accomplished by large umbrella cells that line the inner or luminal surface of the urothelium, and are held together by high resistance tight junctions, and are lined with a unique protein/lipid complex, called a plaque, along their apical membrane.

Now when you think about the bladder, it’s going to cyclically change shape during the course of its normal function.

For example, after you chug a tall mango lassi, your bladder will become completely filled up only to be emptied again when you rush to the restroom. Therefore, the urothelium has to be able to maintain its impermeable properties during these normal changes in bladder shape. Most of this is allowed for by the unfolding of the mucosal surface when the bladder fills up.

When the bladder is empty, this surface is highly wrinkled with rugae which then smooths out as the bladder becomes distended. In addition to this, these umbrella cells of the urothelium, have the ability to stretch with an expanding bladder. In fact, the termtransition” of transitional epithelium refers to this ability to go through transitions of shape.

Cancers that affect the urothelium usually arise through two distinct mechanisms. One way for a urothelial cell carcinoma to arise is through a mutation in the tumor suppressor protein p53.

Mutations in p53 can allow urothelial cells to start growing horizontally like a flat pancake, some of which begin to invade deeper bladder tissues.

The other, less aggressive way for a urothelial cell carcinoma to arise is independent of p53 mutations, and occurs when finger like extensions called papillary tumors grow outward from the urothelium. Although, these can can occasionally invade deeper bladder tissues as well.

Regardless of the cause of the urothelial cell carcinoma invasion, a telltale sign of the presence of the cancer is the presence of red blood cells in the urine, a typically painless condition known as hematuria.

To make a definitive diagnosis, it's possible to look at the inside of the bladder with as cystoscope, which is a thin flexible tube fitted with a light, and a camera that is inserted up the urethra and into the bladder—a procedure called cystoscopy. This tool can also be used to take biopsies which are used for a subsequent histological analysis.

Urothelial cell cancers most commonly occur in older patients, and have been linked to various carcinogens.

Key Takeaways

Transitional cell carcinoma (TCC), also known as urothelial cell carcinoma, is a type of cancer that affects the transitional cells that line the bladder, ureters, and renal pelvis. It is the most common type of bladder cancer, and can cause symptoms such as blood in the urine, painful urination, frequent urination, and back or abdominal pain. TCC is typically treated with a combination of surgery, radiation therapy, chemotherapy, or immunotherapy, and the prognosis depends on the stage and location of the cancer, as well as the individual's overall health. Early diagnosis and treatment can improve the chances of recovery and long-term survival.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014" BMC Cancer (2016)
  6. "Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases" PubMed
  7. "Dilemmas in the treatment of urothelial cancers of the prostate" Urologic Oncology: Seminars and Original Investigations (2009)